The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NAVB | -90% | -100% | -86.85% | -100% |
| S&P | +15.06% | +95.03% | +14.29% | +1,509% |
Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.
Regulatory actions provided the impetus to big moves for these five biotech stocks.
Navidea shares head the wrong way after a thumbs-up from the FDA.
Currently no data to display
Currently no data to display.
Currently no data to display.
| Metric | YoY Change |
|---|
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
